78217-67-1

Usage

Uses

Used in Pharmaceutical Industry:
4,4'-[(PhenylMethyl)iMino]bisbutanenitrile is used as a key intermediate in the synthesis of sym-Homospermidine, an antineoplastic agent. 4,4'-[(PhenylMethyl)iMino]bisbutanenitrile contributes to the development of new therapeutic agents for the treatment of cancer.
As an intermediate in the synthesis of sym-Homospermidine, 4,4'-[(PhenylMethyl)iMino]bisbutanenitrile plays a significant role in the production of a compound with potential antineoplastic properties. This makes it valuable for research and development in the pharmaceutical industry, particularly in the search for novel cancer treatments.

Upstream product

• 628-20-6 4-Chlorobutyronitrile 
• 100-46-9 benzylamine 
• 5332-06-9 4-bromobutanenitrile 
• 497-19-8 sodium carbonate 

Downstream Products

• 78217-68-2 N⁵-Benzylhomospermidine 
• 856869-03-9 N,N-bis(4-amino-4,4-dideuteriobutyl)amine 
• 4427-76-3 sym-homospermidine 
• 622839-31-0 N-trityl-N'-[4-(trityl-amino)-butyl]-butane-1,4-diamine 
• 78217-77-3 N¹,N⁹-bis(2,3-dimethoxybenzoyl)bis(4-aminobutyl)amine 
• 78217-82-0 N⁵--N¹,N⁹-bis(2,3-dihydroxybenzoyl)bis(4-aminobutyl)amine 
• 78217-94-4 N¹,N⁹-bis(2,3-dihydroxybenzoyl)bis(4-aminobutyl)amine hydrobromide 
• 78217-80-8 N⁵--N¹,N⁹-bis(2,3-dimethoxybenzoyl)bis(4-aminobutyl)amine 
• 78217-73-9 N⁵-benzyl-N¹,N⁹-bis(2,3-dimethoxybenzoyl)bis(4-aminobutyl)amine hydrochloride 

Relevant academic research and scientific papers

Alternative spermidine biosynthetic route is critical for growth of Campylobacter jejuni and is the dominant polyamine pathway in human gut microbiota

The availability of fully sequenced bacterial genomes has revealed that many species known to synthesize the polyamine spermidine lack the spermidine biosynthetic enzymes S-adenosylmethionine decarboxylase and spermidine synthase. We found that such speci

Xylylated dimers of putrescine and polyamines: Influence of the polyamine backbone on spermidine transport inhibition

Dimeric norspermidine and spermidine derivatives are strong competitive inhibitors of polyamine transport. A xylyl tether was used for the dimerization of various triamines and spermine via a secondary amino group, and of putrescine via an ether or an amino group. Dimerization of putrescine moieties potentiates their ability to compete against spermidine transport to a much greater extent than for triamine dimers.

Cationic amphiphile/DNA complexes

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cat

Cationic amphiphile compositions for intracellular delivery of therapeutic molecules

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional protons, i.e., it is

Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from ether or ester-linked alkyl groups, and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation.

Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cat

Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cat

Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cat